Trial · NCT03382600
Outcomes13
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) | Up to ~36 months | All participants who received ≥1 dose of study treatment are included. | Percentage of participants | NUMBER |
| SECONDARY | ORR According to Immune-related Response Evaluation Criteria In Solid Tumors (iRECIST) Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | Percentage of participants | NUMBER |
| SECONDARY | Duration of Response (DOR) According to RECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug and had a confirmed response of CR or PR are included. | months | MEDIAN |
| SECONDARY | DOR According to iRECIST Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug and had a confirmed response of CR or PR are included. | months | MEDIAN |
| SECONDARY | Disease Control Rate (DCR) According to RECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | Percentage of participants | NUMBER |
| SECONDARY | DCR According to iRECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | Percentage of participants | NUMBER |
| SECONDARY | Time to Response (TTR) According to RECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | months | MEDIAN |
| SECONDARY | TTR According to iRECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | months | MEDIAN |
| SECONDARY | Progression-free Survival (PFS) According to RECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | months | MEDIAN |
| SECONDARY | PFS According to iRECIST 1.1 Assessed by BICR | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | months | MEDIAN |
| SECONDARY | Number of Participants With ≥1 Adverse Event (AE) | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants Discontinuing From Study Treatment Due to AE(s) | Up to ~36 months | All participants who received ≥1 dose of study drug are included. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03382600/outcomes